866923-62-8

Basic information

• Product Name: Montelukast Cyclopropaneacetonitrile
• Synonyms: Montelukast Cyclopropaneacetonitrile;2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetonitrile
• CAS NO: 866923-62-8
• Molecular Formula: C₃₅H₃₅ClN₂OS
• Molecular Weight: 567.1832
• EINECS: -0
• Mol File: 866923-62-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Montelukast Cyclopropaneacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast Cyclopropaneacetonitrile(866923-62-8)
• EPA Substance Registry System: Montelukast Cyclopropaneacetonitrile(866923-62-8)

Safety Data

• Hazardous Substances Data: 866923-62-8(Hazardous Substances Data)

Usage

Uses

Montelukast Cyclopropaneacetonitrile is an impurity in the synthesis of Montelukast (M568000), a selective leukotriene D4-receptor antagonist. Used as an antiasthmatic.

Upstream product

• 866923-64-0 1-(mercaptomethyl)cyclopropane acetonitrile 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 
• 3132-99-8 m-bromobenzoic aldehyde 
• 4965-33-7 2-methyl-7-chloroquinoline 
• 58824-55-8 1-(3-bromo-phenyl)-prop-2-en-1-ol 
• 1433669-59-0 2-(1-((((R)-1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl) methyl)cyclopropyl)acetonitrile 
• 177748-00-4 7-chloro-2-ethenylquinoline 
• 1015076-76-2 C₁₉H₂₃BrO₄S 
• 762273-01-8 (S)-1-(3-bromo-phenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propan-1-ol 
• 5617-79-8 cyclopropylmethyl mercaptan 
• 75-05-8 acetonitrile 
• 920739-17-9 (S)-benzenepropanol α-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methyl ethyl)-α-methane sulfonate 
• 143-33-9 sodium cyanide 

Downstream Products

• 151767-02-1 Montelukast sodium 
• 577953-88-9 1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt 
• 866923-63-9 (R,E)-2-((1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetamide 
• 158966-92-8 montelukast 
• 936359-29-4 2-(2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl) phenyl)propan-2-ol 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 

Relevant articles and documents

Preparation method of montelukast sodium intermediates

The invention relates to a preparation method of montelukast sodium intermediates. The method comprises the steps that under the protection of inert gas, in solvent, nucleophilic substitution is conducted on a montelukast mother nucleus compound, replaced by various leaving groups, of secondary hydroxyl and various side chains respectively under the action of a catalyst, and various montelukast sodium intermediates are obtained. According to the preparation method of the montelukast sodium intermediates, new catalysts of 4-dimethylaminopyridine and 4-pyrrolidinopyridine are utilized, the reaction is mild in condition and rapid, the product is single, purification is easy and convenient, the obtained intermediates are high in optical purity and higher in yield, and the preparation method is more suitable for industrial production.

Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts

An improved process for the preparation of Montelukast and its pharmaceutically acceptable salts comprises of reacting (S) Benzenepropanol α-[3-[2-(7-chloro2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methyl ethyl)-α-methane sulfonate compound of formula (II) with 1-(mercapto methyl)cyclo propane acetic acid or its ester or nitrile in presence of alkali or alkaline carbonates and/or alkali or alkaline earth metal alkoxide in a suitable polar aprotic solvent with or without combination of C1-C4 alcoholic solvents and then treating with organic amine in a suitable ester and/or acetone and/or aliphatic or aromatic hydrocarbon solvents, and converting the corresponding amine salt compound of montelukast into its sodium salt compound of formula (I) using sodium ion source in methanol, without converting into montelukast free acid.

PROCESS

A process of preparing montelukast, or a pharmaceutically acceptable salt thereof, which process comprises reacting a protected intermediate of formula (II) as defined in the specification with a cyclopropyl intermediate.